Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Prognostic benefit of TILs independent of clinicopathological and molecular factors

British Journal of Cancer volume 129, pages 737–738 (2023)Cite this article

Subjects

We would like to thank Almangush et al. [1] for their interest in our recent review in the British Journal of Cancer, “Tumour-infiltrating lymphocytes: from prognosis to treatment selection” [2] and we would like to share our thoughts regarding their letter.

We fully agree with the authors that there are many additional important aspects of Tumour-infiltrating lymphocytes (TILs) across different facets of clinical care, for example within the tumour-node-metastasis (TNM)-Immune classification. Regretfully we were not able to elaborate on all of these aspects within the confines of our original manuscript.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Data availability

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

References

  1. Almangush A, Mäkitie AA, Leivo I. Can TILs supplement the TNM staging system (as TNM-Immune)?

  2. Brummel K, Eerkens AL, de Bruyn M, Nijman HW. Tumour-infiltrating lymphocytes: from prognosis to treatment selection. Br J Cancer. 2023;188:451–8.

  3. Ward MJ, Thirdborough SM, Mellows T, Riley C, Harris S, Suchak K, et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. Br J Cancer. 2014;110:489–500.

    Article  CAS  PubMed  Google Scholar 

  4. Wakeham K, Murray L, Muirhead R, Hawkins MA, Sebag-Montefiore D, Brown S, et al. Multicentre investigation of prognostic factors incorporating p16 and tumour infiltrating lymphocytes for anal cancer after chemoradiotherapy. Clin Oncol. 2021;33:638–49.

    Article  CAS  Google Scholar 

  5. Getz G, Gabriel SB, Cibulskis K, Lander E, Sivachenko A, Sougnez C, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.

    Article  CAS  Google Scholar 

  6. Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Léon-Castillo A, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun. 2022;13:1373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Horeweg N, de Bruyn M, Nout RA, Stelloo E, Kedzierska K, León-Castillo A, et al. Prognostic integrated image-based immune and molecular profiling in early-stage endometrial cancer. Cancer Immunol Res. 2020;8:1508–19.

    Article  CAS  PubMed  Google Scholar 

  8. Lee M, Park IA, Heo SH, Kim YA, Gong G, Lee HJ. Association between p53 expression and amount of tumor-infiltrating lymphocytes in triple-negative breast cancer. J Pathol Transl Med. 2019;53:180–7.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

Funding

Not applicable.

Author information

Author notes

  1. These authors contributed equally: Koen Brummel, Anneke L. Eerkens.

  2. These authors jointly supervised this work: Marco de Bruyn, Hans W. Nijman.

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

    Koen Brummel, Anneke L. Eerkens, Marco de Bruyn & Hans W. Nijman

Authors
  1. Koen Brummel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anneke L. Eerkens
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco de Bruyn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans W. Nijman
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KB and ALE drafted and revised the manuscript. MB and HWN conceived the project, supervised writing, and revised the manuscript. All authors read and approved the final version.

Corresponding author

Correspondence to Hans W. Nijman.

Ethics declarations

Competing interests

HWN and MdB hold a patent on antibodies targeting CD103 (no 62/704,258).

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors have approved to publish this manuscript.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brummel, K., Eerkens, A.L., de Bruyn, M. et al. Prognostic benefit of TILs independent of clinicopathological and molecular factors. Br J Cancer 129, 737–738 (2023). https://doi.org/10.1038/s41416-023-02335-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41416-023-02335-6

Search

Advanced search

Quick links